Rain Therapeutics is developing targeted therapies for cancer patients. Precision oncology prioritizes pairing drugs with cancer patients and underlies Rain’s development philosophy. Rain is designing drugs to target aberrant genetic or cell signaling networks in cancer and is employing diagnostic assays to identify biomarkers predictive of efficacy. This involves tumor genetic testing with the aim of maximizing patient benefit. Rain’s lead drug candidate, milademetan, is currently in clinical development for patients with liposarcoma. Milademetan is an oral small molecule inhibitor of MDM2, which is commonly over-amplified in cancer. Rain also has a research program in preclinical development targeting the DNA damage response pathway and RAD52.